CLARITY PHARMACEUTICALS LTD

1.72%

$3.15

Market Cap $1.193B

Healthcare Biotechnology

Clarity Pharmaceuticals Ltd is an Australia-based clinical-stage radiopharmaceutical... Clarity Pharmaceuticals Ltd is an Australia-based clinical-stage radiopharmaceutical company. The Company is focused on developing theranostic (therapy and imaging) products, based on its platform SAR Technology. It is progressing seven clinical trials with its three key products, SARTATE, SAR-bisPSMA, and SAR-Bombesin. SARTATE is developed for diagnosing, staging, and treating cancers that express somatostatin receptor 2 (SSTR2), including neuroblastoma and neuroendocrine tumors (NETs). SAR-bisPSMA is developed for diagnosing, staging, and treating cancers that express Prostate Specific Membrane Antigen (PSMA). SAR-Bombesin is developed for identifying and selecting patients for subsequent treatment of cancers that express a specific receptor called the gastrin releasing peptide receptor (GRPr), including breast cancer and prostate cancer. It has a diverse range of products in clinical trials, which address both large indications as well as rare and orphan indications of cancer.More

(ASX:SNT)

Syntara Limited (ASX:SNT), headquartered in Frenchs Forest, New South Wales, is a clinical stage biotechnology company focused on developing novel therapies for fibrotic diseases and rare haematological disorders.

Latest Threads

Tag

Subject

CU6

CU6 - ASX Charts

121 122 123

23:44

7.3K

2.1M

23:44

Last post nugett

7.3K

2.1M

CU6

CU6 - Media and Industry News

31 32 33

19:01

1.9K

759K

19:01

Last post Vivo

1.9K

759K

CU6

One Platform Endless Opportunities

15:17

3.3K

15:17

Last post Johnnykb

3.3K

CU6

Ann: Clarity signs a Commercial Manufacturing Agreement

16/04/26

18K

16/04/26

Last post Mynodue

18K

CU6

Ann: Ceasing to be a substantial holder

10/04/26

397

10/04/26

Last post

ASX News

397

CU6

Industry Analysis

10/04/26

983

10/04/26

Last post BioInv2025

983

CU6

Ann: Becoming a substantial holder

09/04/26

903

09/04/26

Last post Hingdog

903

CU6

Ann: Director Appointment/Resignation

09/04/26

1.8K

09/04/26

Last post frenchfries57

1.8K

See All Discussions

Timeline

Clarity signs a Commercial Manufacturing Agreement
14 Apr 08:33	Share

Ceasing to be a substantial holder
10 Apr 17:01	Share

Becoming a substantial holder
09 Apr 16:12	Share

Final Director's Interest Notice - Biggin
09 Apr 09:42	Share

Director Appointment/Resignation
09 Apr 08:57	Share

Notification regarding unquoted securities - CU6
07 Apr 11:22	Share

Cleansing Notice
31 Mar 17:15	Share

Application for quotation of securities - CU6
31 Mar 17:11	Share

Co-PSMA data published in the European Urology journal
31 Mar 09:20	Share

Becoming a substantial holder
26 Mar 08:16	Share

Clarity signs a large-scale Manufacturing Supply Agreement
25 Mar 09:24	Share

Co-PSMA data presented
17 Mar 09:40	Share

Cleansing Notice
11 Mar 12:34	Share

Application for quotation of securities - CU6
11 Mar 12:28	Share

AMPLIFY trial - Target number of participants achieved
10 Mar 09:03	Share

Notification regarding unquoted securities - CU6
02 Mar 11:41	Share

Half Year Accounts
27 Feb 09:51	Share

Half Yearly Report and Accounts
27 Feb 09:48	Share

SECuRE trial update
23 Feb 09:00	Share

Co-PSMA abstract released
16 Feb 09:42	Share

Change in substantial holding
12 Feb 17:27	Share

Quarterly Activities/Appendix 4C Cash Flow Report
30 Jan 10:50	Share

SECuRE trial to continue with no modifications to protocol
15 Jan 09:46	Share

Notification of cessation of securities - CU6
07 Jan 16:45	Share

Co-PSMA abstract accepted for oral presentation at EAU
24 Dec 10:02	Share

Positive guidance from the US FDA on Cu-64 SARTATE Phase III
22 Dec 09:19	Share

Clarity to present DISCO trial data at ASCO-GI 2026
09 Dec 09:56	Share

Notification regarding unquoted securities - CU6
08 Dec 12:24	Share

Notification regarding unquoted securities - CU6
02 Dec 14:37	Share

Ceasing to be a substantial holder
01 Dec 08:14	Share

View More

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.


Last $3.15		Change -0.055(1.72%)		Mkt cap ! $1.193B

Open	High	Low	Volume
$3.18	$3.23	$3.13	1.325M

Buyers (Bids)

Vol.	Price($)
18090	$3.13

Sellers (Offers)

Price($)	Vol.
$3.15	13500

Last trade - 16.25pm 17/04/2026 (20 minute delay)

CU6 (ASX) Chart

CLARITY PHARMACEUTICALS LTD

Latest Threads

Eden Innovations (ASX: EDE) - New Edenshield® division to commercialise Eden products to Military, Defence & Infrastructure Markets

Timeline

Featured News

Latest Videos

Clarity Pharmaceuticals' (ASX:CU6) theranostic prostate cancer trial progresses to highest dose level

10 Aug 2023 12:13 (AEST)

Latest Articles

Clarity scribes deal on delivery of copper 64 isotopes

Clarity Pharmaceuticals Ltd has seen its share price leap after it announced a deal with Nusano to deliver Cu-64 isotopes

Another win for Clarity at FDA as imaging agent fast-tracked for complex prostate cancer

For those unlucky enough to have received a testicular castration to treat prostate cancer, only for it to come back, Clarity Pharmaceuticals’ (ASX:CU6) news on Wednesday morning could offer crucial moral support.For those patients (who have also already received first-stage less ...

Clarity jumps as FDA awards fast track status for PET scan imaging agent

Clarity Pharmaceuticals (ASX:CU6) has seen the U.S. FDA fast-track its prostate cancer imaging compound for use in PET scans on patients with recurring prostate cancer. The stock jumped 4% in the first hour of trade to $4.23 in what is likely a welcome move for shareholders who have already seen ...

Buyers (Bids)

Sellers (Offers)

Top Stories

Featured News